t
Aptamer Group plc announced on 08 August 2025 an Investor Technical Webinar. Dr David Bunka, Chief Scientific Officer, will host the webinar on Thursday, 14 August 2025, at 6:00 pm (BST) to provide an update on the Company's technical development programmes. The event is open for registration to shareholders and other interested parties.
| Date | 8 Aug 2025 |
| Time | 07:00:12 |
| Category | Miscellaneous |
| ID | 5063U |
8 August 2025
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Investor Technical Webinar
Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, is pleased to announce that Dr David Bunka, Chief Scientific Officer, will host a webinar to provide an update on the Company's progress within its technical development programmes.
The webinar will be broadcast on Thursday, 14 August 2025, at 6:00 pm (BST) and will offer a detailed review of the latest data and technical developments, building on insights shared through recent regulatory announcements.
The webinar is open to shareholders and other interested parties who can register for the event by using the following link: https://www.turnerpope.com/register/
- Ends -
For further information, please contact:
|
Aptamer Group plc Dr Arron Tolley, Chief Executive Officer |
+44 (0) 1904 217 404 |
|
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Jade Bayat |
+44 (0) 20 3368 3550 |
|
Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker |
+44 (0) 20 3657 0050 |
|
Northstar Communications Limited - Investor Relations Sarah Hollins |
+44 (0) 113 730 3896 |
About Aptamer Group
Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.
Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.
Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.
To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/